Stone Pharmaceutical Group: GLP-1/GIP receptor dual biased agonist long-acting peptide injection approved for FDA clinical trial.

According to the announcement by the Stone Pharmaceuticals Group on the Hong Kong Stock Exchange, the company's board of directors gladly announced that the long-acting injection of GLP-1/GIP receptor biased agonist peptide developed by the group has been approved by the US Food and Drug Administration for clinical trials in the United States. The approved clinical indication for this approval is weight management in patients who are obese or overweight with at least one weight-related co-morbidity. Additionally, SYH2082 also has the potential to improve blood sugar control in adult patients with type 2 diabetes, providing additional clinical benefits.